JPMorgan Chase & Co. Raises Humana (NYSE:HUM) Price Target to $396.00

Humana (NYSE:HUM) had its target price raised by equities research analysts at JPMorgan Chase & Co. from $332.00 to $396.00 in a research report issued on Wednesday, Benzinga reports. The firm currently has a “neutral” rating on the insurance provider’s stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 10.93% from the company’s previous close.

A number of other research analysts also recently commented on the company. UBS Group lowered their price objective on Humana from $334.00 to $326.00 and set a “neutral” rating for the company in a research note on Thursday, April 25th. Royal Bank of Canada reduced their price objective on shares of Humana from $415.00 to $353.00 and set an “outperform” rating for the company in a research report on Thursday, April 25th. Oppenheimer lifted their target price on Humana from $370.00 to $400.00 and gave the stock an “outperform” rating in a report on Thursday, August 1st. Deutsche Bank Aktiengesellschaft boosted their price target on shares of Humana from $341.00 to $349.00 and gave the company a “hold” rating in a report on Friday, August 2nd. Finally, TD Cowen lifted their target price on Humana from $396.00 to $407.00 and gave the company a “buy” rating in a research note on Wednesday, July 24th. Thirteen analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $396.35.

Humana Stock Performance

Shares of NYSE HUM remained flat at $356.98 during midday trading on Wednesday. 91,280 shares of the stock were exchanged, compared to its average volume of 1,667,002. The stock’s 50-day simple moving average is $367.78 and its 200 day simple moving average is $346.46. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.67. The stock has a market capitalization of $43.02 billion, a P/E ratio of 22.28, a P/E/G ratio of 2.09 and a beta of 0.51. Humana has a 1-year low of $298.61 and a 1-year high of $530.54.

Humana (NYSE:HUM) last issued its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 EPS for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. The company had revenue of $29.54 billion for the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The firm’s quarterly revenue was up 10.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $8.94 earnings per share. On average, analysts forecast that Humana will post 16.14 earnings per share for the current year.

Institutional Trading of Humana

Institutional investors have recently added to or reduced their stakes in the stock. Cetera Trust Company N.A acquired a new position in Humana during the 4th quarter worth approximately $28,000. CarsonAllaria Wealth Management Ltd. grew its position in shares of Humana by 111.4% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after acquiring an additional 39 shares during the period. Private Wealth Management Group LLC bought a new position in shares of Humana during the 4th quarter worth $32,000. Hantz Financial Services Inc. purchased a new stake in Humana during the second quarter valued at about $35,000. Finally, Family Firm Inc. bought a new position in Humana during the second quarter worth about $37,000. 92.38% of the stock is currently owned by institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.